CSL Ltd Annual Report 2020

Brian McNamee AO MBBS, FTSE Age 63 Chairman and independent Non- executive Director Director of CSL Limited since February 2018 and Chairman fromOctober 2018 Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee has a broad global perspective and understanding of long-term capital projects in the pharmaceutical industry, with proven health, safety, environment and corporate responsibility. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a Senior Advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Other directorships and offices (current and recent): – Chairman of GenesisCare Limited (from July 2019). Board Committee memberships: – Chairman of the Innovation and Development Committee. – Member of the Corporate Governance and Nomination Committee. – Member of the Securities & Market Disclosure Committee. Paul Perreault BA (Psychology) Age 63 Non-independent Executive Director Director of CSL Limited since February 2013, and appointed Chief Executive Officer and Managing Director in July 2013 Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. He was appointed Chief Executive Officer and Managing Director of CSL Limited in July 2013, and was appointed to the CSL Board of Directors the same year. Since then, CSL has grown to become the fifth largest biotech company in the world with more than 25,000 employees bringing lifesaving medicines to people in more than 100 countries. Mr Perreault, who previously served as CSL Behring’s president, joined CSL in 2004 with the acquisition of Aventis Behring. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer. Mr Perreault holds a bachelor’s degree in psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business. Board Committee memberships: – Member of the Innovation and Development Committee. – Member of the Securities & Market Disclosure Committee. Andrew Cuthbertson AO BMedSci, MBBS, PhD, FAA, FTSE, FAHMS Age 65 Non-independent Executive Director Director of CSL Limited since October 2018, and appointed Chief Scientific Officer and R&D Director in 2000 and Senior Adviser to the CEO in July 2020. Professor Cuthbertson has over 35 years’ experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non-executive director experience. Professor Cuthbertson joined CSL in April 1997 as the director of research. Prior to CSL, he was a senior scientist at Genentech Inc, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life-threatening diseases. After completing medical training at the University of Melbourne and a PhD in immunology at the Walter and Eliza Hall Institute in Australia, Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia, and the National Institutes of Health in Maryland, US. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. Other directorships and offices (current and recent): – Director of the Centre of Eye Research Australia (since March 2017); – Director of the Grattan Institute (since January 2019); and – Member of the Council of the University of Melbourne (since January 2020). Board Committee memberships: – Member of the Innovation and Development Committee. Bruce Brook BCom, BAcc, FCA, MAICD Age 65 Independent Non-executive Director Director of CSL Limited since August 2011 Mr Brook has an extensive breadth of executive experience in diverse industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has valuable insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was Chief Financial Officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including Deputy Chief Finance Officer of ANZ Banking Group Limited, Group Chief Accountant of Pacific Dunlop Limited and General Manager, Group Accounting positions at CRA Limited and Pasminco Limited. Other directorships and offices (current and recent): – Director of Guide Dogs Victoria (since November 2018); – Director of Incitec Pivot Limited (since December 2018); – Director of Newmont Corporation (since October 2011); – Former Director of the Deep Exploration Technologies Co-operative Research Center Limited (from August 2011 to September 2018); and – Former Director and Chairman of Programmed Group (from June 2010 to October 2017). Board Committee Memberships: – Chairman of the Audit and Risk Management Committee. – Member of the Corporate Governance and Nomination Committee. CSL Limited Annual Report 2020 55 Board of Directors